BMJ Open · 2013 · 28 citations · 11 references
MedicineGynecologyPharmacotherapyClinical PharmacologyMaternal-fetal MedicineReproductive MedicineEctopic PregnancyHigh-risk Pregnancy ManagementPreclinical Drug EvaluationPreclinical Safety EvaluationPregnancyTubal Factor InfertilityCombination TherapyEpidermal Growth Factor Receptor InhibitionEpidermal Growth Factor Receptor SignalingPharmacotherapy In PregnancySerum Human Chorionic Gonadotropin MonitoringSingle-arm TrialsTubal Factor Infertility Pharmacotherapy
INTRODUCTION: Tubal ectopic pregnancy (tEP) is the most common life-threatening condition in gynaecology. tEPs with pretreatment serum human chorionic gonadotrophin (hCG) levels <1000 IU/L respond well to outpatient medical treatment with intramuscular methotrexate (MTX). TEPs with hCG >1000 IU/L take a significant time to resolve with MTX and require multiple outpatient monitoring visits. Gefitinib is an orally active epidermal growth factor receptor (EGFR) antagonist. In preclinical studies, we found that EP implantation sites express high levels of EGFR and that gefitinib augments MTX-induced regression of pregnancy-like tissue. We performed a phase I toxicity study administering oral gefitinib and intramuscular MTX to 12 women with tEPs. The combination therapy did not cause significant toxicities and was well tolerated. We noted that combination therapy resolved the tEPs faster than MTX alone. We now describe the protocol of a larger single arm trial to estimate the efficacy and side effects of combination gefitinib and MTX to treat stable tEPs with hCG 1000-10 000 IU/L METHODS AND ANALYSIS: We propose to undertake a single-arm multicentre open label trial (in Edinburgh and Melbourne) and recruit 28 women with tEPs (pretreatment serum hCG 1000-10 000 IU/L). We intend to give a single dose of intramuscular MTX (50 mg/m(2)) and oral gefitinib (250 mg) daily for 7 days. Our primary outcome is the resolution of EP to non-pregnant hCG levels <15 IU/L without requirement of surgery. Our secondary outcomes are comparison of time to resolution against historical controls given MTX only, and safety and tolerability as determined by clinical/biochemical assessment. ETHICS AND DISSEMINATION: Ethical approval has been obtained from Scotland A Research Ethics Committee (MREC 11/AL/0350), Southern Health Human Research Ethics Committee B (HREC 11180B) and the Mercy Health Human Research Ethics Committee (R12/25). Data will be presented at international conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: ACTRN12611001056987.
11
United States Food and Drug Administration Drug Approval Summary
Martin H. Cohen, Grant A. Williams, Rajeshwari Sridhara et al. · Clinical Cancer Research · 2004 · 500 citations
Medicine, Oncology, Pharmacology +15
Sample size tables for exact single‐stage phase II designs
Roger A’Hern · Statistics in Medicine · 2001 · 398 citations
Diagnosis and management of ectopic pregnancy
Vanitha N. Sivalingam, W. Colin Duncan, E. Kirk et al. · Journal of Family Planning and Reproductive Health Care · 2011 · 326 citations · Full text
Medicine, Gynecology, Obstetrics +7
Diagnosis and management of ectopic pregnancy
D. Jurkovic, Hazel Wilkinson · BMJ · 2011 · 138 citations
Medicine, Gynecology, Obstetrics +7